Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.42 |
| ▸ | RAF1 | P04049 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 8/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | GALK1 | P51570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338399 | 0.96 | PTGES (0.43) | BRAFRAF1GRM5PTGESKDR | |
| SCHEMBL1337161 | 0.92 | PTGES (0.48) | BRAFRAF1PTGESKDRDYRK1A | |
| SCHEMBL1338370 | 0.92 | PTGES (0.44) | BRAFRAF1GRM5PTGESKDR | |
| SCHEMBL1337365 | 0.90 | PTGES (0.53) | BRAFRAF1PTGESEPAS1 | |
| SCHEMBL1337925 | 0.87 | PTGES (0.45) | BRAFRAF1PTGESKDRDYRK1A | |
| SCHEMBL1338989 | 0.86 | BRAF (0.45) | BRAFRAF1PTGESKDRDYRK1A | |
| SCHEMBL12131891 | 0.85 | PTGES (0.46) | BRAFRAF1GRM5PTGESKDR | |
| SCHEMBL1337997 | 0.83 | BRAF (0.47) | BRAFRAF1PTGESKDR | |
| SCHEMBL12131892 | 0.81 | PTGES (0.44) | BRAFRAF1PTGESKDRDYRK1A | |
| SCHEMBL1338738 | 0.80 | PTGES (0.45) | BRAFRAF1PTGESKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598190-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | claimed |
| US-20110275656-A1 | 3H-Imidazo [4, 5-C] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | claimed |
| US-8598190-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20110275656-A1 | 3H-Imidazo [4, 5-C] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275656-A1 | 3H-Imidazo [4, 5-C] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, IL4, MAP7D3 | BRAF 967/4885RAF1 1237/4885GRM5 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.